Human papillomavirus (HPV) vaccination and cervical screening are complementary prevention measures targeting reductions in cervical precancer and cancer and other genital and oropharyngeal cancers. To maximize populationwide benefits for cervical cancer prevention, integration of vaccination and screening is critical to improve overall benefits and reduce harms and redundancies in health care costs.
Over the past decade, population-level HPV vaccination coverage has increased,1 and changes in cervical cancer screening guideline recommendations have occurred.2-5 Population-level incidence of cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3 was previously reported for individuals aged 15 to 29 years from 2007 to 2014.6 The current cohort study updated this previous report with 6 additional years of CIN ascertainment.